Risedronic acid

Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) [1][2][3].

Product Specifications

CAS Number

[105462-24-6]

Product Name Alternative

Risedronate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis

Field of Research

Cancer; Infection; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Risedronic-acid.html

Purity

99.84

Solubility

0.1 M NaOH : 11 mg/mL (ultrasonic; adjust pH to 7 with NaOH) |H2O : 5.47 mg/mL (ultrasonic)

Smiles

OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=CC=C1

Molecular Formula

C7H11NO7P2

Molecular Weight

283.11

Precautions

H302, H315, H319, H335

References & Citations

[1]Fujita H, et al. Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells. Basic Clin Pharmacol Toxicol. 2011 Aug;109 (2) :78-84. |[2]Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55 (5) :2026-31.|[3]Willey JS, et al. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations. Bone. 2010 Jan;46 (1) :101-11.